Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Precision BioSciences Inc Market Cap
Based on ratings from 0 stock analysts, the Precision BioSciences Inc stock price is expected to increase by 220.39% in 12 months. This is calculated by using the average 12-month stock price forecast for Precision BioSciences Inc. The lowest target is $19 and the highest is $60. Please note analyst price targets are not guaranteed and could be missed completely.
DTIL is a stock in Health Care which has been forecasted to be worth $33 as an average. On the higher end, the forecast price is $60 USD by Patrick Trucchio from HC Wainwright & Co. and on the lower end DTIL is forecasted to be $19 by Debjit Chattopadhyay from HC Wainwright & Co..
These are the latest 20 analyst ratings of DTIL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Reiterates | Aug 22, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Reiterates | May 30, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Reiterates | May 16, 2024 |
| Debjit Chattopadhyay Guggenheim | Buy | $19 | Initiates | Apr 30, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Reiterates | Apr 17, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $60 | Maintains | Mar 28, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $3 | Reiterates | Feb 14, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $3 | Reiterates | Sep 19, 2023 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $3 | Maintains | Aug 17, 2023 |
| Patrick Trucchio HC Wainwright & Co. | Buy | Reiterates | Aug 7, 2023 | |
| Patrick Trucchio HC Wainwright & Co. | Buy | $5 | Reiterates | Jul 28, 2023 |
| Thomas Shrader BTIG | Buy | $2 | Maintains | Jul 28, 2023 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $17 | Reiterates | Jun 1, 2023 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $17 | Reiterates | Mar 15, 2023 |
| Kostas Biliouris BMO Capital | Market Perform | $4 | Downgrade | Mar 14, 2023 |
| Salveen Richter Goldman Sachs | Neutral | $1 | Maintains | Nov 10, 2022 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $17 | Maintains | Nov 10, 2022 |
| Salveen Richter Goldman Sachs | Neutral | $2 | Maintains | Aug 9, 2022 |
BMO Capital | Outperform | Initiates | Jun 17, 2022 | |
William Blair | Market Perform | Downgrade | Jun 9, 2022 |
When did it IPO
2019
Staff Count
110
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Michael Amoroso
Market Cap
$70.3M
In 2023, DTIL generated $48.7M in revenue, which was a increase of 94.15% from the previous year. This can be seen as a signal that DTIL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 26 Oct 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present two posters at the ESGCT 30th Annual Congress that highlight ARCUS' differentiated ability to make efficient, durable, and targeted insertion edits in non-human primates (N.
Mon, 23 Oct 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference taking place October 25, 2023. Details for the virtual fireside chat are as follows: Date: Wedne.
Thu, 12 Oct 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that two abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for poster presentations at the upcoming Congress on October 24-27, 2023, in Brussels, Belgium. Presentat.
Wed, 27 Sep 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 18/161,560, titled “Engineered Meganucleases That Target Human Mitochondrial Genom.
Tue, 12 Sep 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the Company plans to highlight its current development programs, pipeline updates, and underlying ARCUS platform technology during a virtual R&D Day to be held today at 9:00 AM ET. “At Precision, we are moving forward with a renewed identity and focus on our core foundationa.
Wed, 06 Sep 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that members of management will participate in the following investor conferences in the month of September: H.C. Wainwright Annual Global Investment Conference 2023 Date: September 11, 2023 Time: Available on-demand at 7:00 am ET Jefferies Gene Editing/Gene Therapy Summit Date: September 27, 2023 T.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
